R 170591

Drug Profile

R 170591

Alternative Names: JNJ-2408068

Latest Information Update: 03 Oct 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen L.P.
  • Class Antivirals
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Respiratory syncytial virus infections

Most Recent Events

  • 03 Oct 2005 Discontinued - Preclinical for Respiratory syncytial virus infections in Belgium (Inhalation)
  • 05 May 2001 Preclinical development for Respiratory syncytial virus infections in Belgium (Inhalation)
  • 05 May 2001 A preclinical study has been added to the Viral Infections antimicrobial activity and pharmacodynamics sections and the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top